Drug profile · INN
ziv-aflibercept
ZALTRAP
ziv-aflibercept (ZALTRAP) is a placenta growth factor inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — ziv-aflibercept
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 10
- Data quality
- 0.84
Quick answer
ziv-aflibercept (ZALTRAP) is a placenta growth factor inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Placenta growth factor inhibitor
Primary target: Placenta growth factor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ziv-aflibercept?
ziv-aflibercept (ZALTRAP) is a placenta growth factor inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ziv-aflibercept?
ZALTRAP is a marketed brand name for ziv-aflibercept. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ziv-aflibercept?
ziv-aflibercept has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.